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Following an outbreak  of epidemic meningitis at  Camp  Funston, 
Kansas,  in  October and  November, 1917,  a  series  of antimeningitis 
vaccinations was  undertaken on volunteer subjects from  the  camp. 
Major E. H. Schorer, Chief of the Laboratory Section at the adjacent 
Base Hospital  at  Fort Riley, offered every facility at his  command 
and cooperated in  the laboratory work connected with the vaccina- 
tions.  In  the  camp,  under  the  direction of  the  Division  Surgeon, 
Lieutenant Colonel J. L. Shepard, a preliminary series of vaccinations 
on a  relatively small number  of  volunteers served to determine  the 
appropriate doses and the resultant local and general reactions.  Fol- 
lowing this series, the vaccine was offered by the Division Surgeon to 
the camp at  large,  and "given by the  regimental surgeons to  all who 
wished to  take it. 
Preliminary Series. 
The  preliminary  series  of  vaccinations  was  carried  out  in  the 
342nd  Field  Artillery  Regiment  through  the  courtesy  of  Colonel 
Nugent and Major Czar C. Johnson, surgeon of the regiment.  This 
organization volunteered en masse in response to the call issued by the 
Division  Surgeon and  offered a  most  promising  opportunity  for  an 
extended series of observations.  Moreover, only one case of meningi- 
tis had developed in the 342nd Field Artillery and the regiment had 
recently been covered in the search for meningococcus carriers.  Dur- 
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ing the first experience the vaccination of known  carriers was avoided 
and  this regiment appeared  to be free from  them. 
Choice and  Preparation  o r Vacc'ne.--That  at  least two  serologically distinct 
disease-producing types of  meningococci  exist  has  been  known  since  Dopter  a 
in 1909  described the "parameningococcus" obtained first from the nasopharynx 
and then from the blood and spinal fluid of active cases of epidemic meningitis. 
Following  Dopter's  discovery Wollstein  2 confirmed  the  serological distinction 
between  normal or regular meningococciand parameningococci by a comparative 
study of agglutination, opsonization, and complement fixation of the two types, 
concluding that : 
"Because of the variations and irregularities of serum reactions existing among  other- 
wise normal strains of meningococci it does not seem either possible or desirable to  sepa- 
rate the parameningococci  into a strictly definite class.  It appears desirable to consider 
them as constituting a special strain among meningococci not, however, wholly consistent 
in itself." 
In  a  more recent  study based on absorption of agglutinin and agglutination 
tests Gordon  3 has distinguished four groups of meningococci which be calls Types 
I. II, III, and IV.  Groups I  and II are distinct and correspond to the known 
types.  They are responsible for 75 to 85 per cent of the cases of epidemic menin- 
gitis.  Other meningococci he separates into Types III and IV.  Tulloch  4 finds, 
however, that definite group relationships exist between Types I  and III, and II 
and IV, so that a I-III group type and a II-IV group type can be distinguished. 
These and certain other strains can be classified only by the absorption of ag- 
glutinin test, since they agglutinate in two or more of the type sera.  Type II 
also ' appears to include a  complex subgroup and  shows considerable variation 
among the cocci comprised therein."  Nicolle, Debains, and Jouan, 5 employing 
a rapid method of agglutination or flocculation (without incubation) in low dilu- 
1 Dopter,  C.,  t~tude  de quelques germes isol6s du  rhino-pharynx, voisins du 
m6ningocoque  (param6ningocoques), Compt.  rend.  Soc.  biol.,  1909,  lxvii, 74. 
2 Wollstein, M.,  Parameningococcus and  its antiserum,  J.  Exp.  Med.,  1914, 
xx, 201. 
Gordon,  M.  H.,  The  definition  of  the  meningococcus,  National  Health 
Insurance, Med. Research Committee, Special Rep. Series, No. 3, London, 1917,  10. 
4 Tulloch, W. J., A study of the mechanism of the agglutination and absorption 
of agglutinin reaction, together with an examination of the  efficacy of these tests 
for identifying specimens of the meningococcus isolated from 354  cases of cere~ 
brospinal fever, J. Roy. Army Med. Corps, 1918, xxx, 115. 
5 Nicolle, M., Debains, E., and Jouan,  C., Sur les m6ningocoques et les s6rums 
antim~ningococciques,  Bull.  el m~m.  Soc.  m~d. hop.  Paris',  1917,  xli, 878; Ann. 
Inst. Pasteur, 1918, xxxii, 150. FREDERICK L.  GATES  451 
t'ons of immune horse serum, have also reported four types of the meningococcus 
whfch they designate A (Gordon I  and III, regular meningococcus),  B (Gordon 
II and IV, parameningococcus), C, and D.  Types A and B are common, Types 
C and D relatively rare.  They find that certain meningococci are related to two 
or more of their specific types and must therefore be classed as "indeterminates." 
In a recent article Mathers and Herrold  6 readily distinguish  the two main types 
by agglutination, and group around them most of their atypical strains.  The 
strains which fail to agglutinate in type sera bave nevertheless similar  antigenic 
properties, since "monovalent serum prepared from these strains agglutinates in a 
specific way meningococci  belonging  to one or the other of t~e large biologic 
groups." 
It  appears,  therefore,  that  while  two  distinct  types  or  groups  of 
meningococci  may  be  clearly  differentiated,  most of the other organ- 
isms that do not fall strictly within these two groups are either inter- 
mediates or irregular variants of one or the other.  Meningococci of 
other types in  as far as they can  be distinguished  are only occasion- 
ally responsible for a  case of epidemic meningitis. 
In  order  to  cover  the  two  pathogenic  types  of meningococci and 
variants  of them, it  has become the practice in  this  country,  follow- 
ing the methods of Flexner and Jobling 7 and Amoss and Wollstein, 8 to 
prepare  highly polyvalent therapeutic sera  by the repeated injection 
of a  number of representative  strains  with  the  object of producing 
a  serum which would protect against any pathogenic strain that might 
be encountered.  For protective inoculation high polyvalency would 
seem  to  be  equally  desirable,  but  the  choice  of  strains  for  human 
vaccination  is limited  by the fact that only a few injections are practi- 
cable, whereas the production of therapeutic serum requires a long series 
of inoculations in which immunity is gradually built up by the repeated 
injection of small  doses of each antigen.  The inclusion of any con- 
siderable number of strains in a  vaccine for human use might defeat 
the purpose of the vaccination by the introduction of toxic amounts 
of bacterial protein without a  sufficient quantity of any one specific 
Mathers, G., and Herrold, R. D., Observations on meningococcus carriers and 
on the bacteriology of epidemic meningitis,  J. Infect. Dis., 1918, xxii, 523. 
Flexner, S., and Jobling,  J. W.,  Serum treatment of epidemic  cerebro-spinal 
meningitis, J. Exp. Med., 1908, x, 141. 
8 Amoss, H. L., and Wollstein, M., A method for the rapid preparation of anti- 
meningitis serum, J. Exp. Med.,  1916, xxiii, 403. 452  ANTIMENINGITIS  VACCINATION 
antigen to give rise to protection against its given strain.  But since 
70  to 85  per cent of the cases of epidemic meningitis are caused by 
meningococci of  the two main types, the limitation of the  strains  in 
a  vaccine  to  representatives  of  these  types would  seem  to  be  the 
rational  procedure,  holding  out  hope  of protection  against  a  large 
proportion of disease-producing strains. 
Therefore, for the vaccine used at Camp Funston only three organ- 
isms were chosen from the stock of The Rockefeller Institute, but the 
vaccine may be regarded as having represented the two main types 
of  the  meningococcus.  It was also anticipated that the epidemic at 
Camp Funston might furnish some strain or strains of meningococci 
not closely related to the main types and which ought therefore to be 
included in the vaccine, but a  type study at Fort Riley showed that 
the sixteen strains recovered from active cases in December and Jan- 
uary  would  be  covered  by  a  vaccine containing normal  and  para 
strains. 
Method of Preparing  Vaccine.--The  vaccine used was made in  the 
laboratory  of  The  Rockefeller Institute.  16 hour growths on  1 per 
cent  glucose  agar  in  Blake bottles were washed off with isotonic salt 
solution,  like  strains  pooled,  and  the  concentrated suspensions im- 
mediately heated to 65°C.  for 30 minutes to kill the cocci and inac- 
tivate  the  autolytic  ferment.  Experiments  have  shown  that  this 
temperature does not impair the antigenic properties of the organism 
and the intact cocci are less toxic than their autolyzed products. 
Following the usual  tests  for purity  and  sterility the  suspensions 
were standardized, diluted in 0.85 per cent salt solution, mixed in equal 
proportions  of  the  three  strains  in  concentrations  of  1,000  million, 
2,000  million, 4,000  million, and 8,000  million cocci per cc. and pre- 
served  with  0.35  per cent tricresol. 
All the injections in the preliminary series were made strictly sub- 
cutaneously with a fine needle (No. 25)  at the insertion of the deltoid 
muscle,  usually in  the  left arm unless a  recent vaccina "take"  had 
occurred.  Then  the  right  arm  was  used.  The  tincture  of  iodine 
used as antiseptic was then sponged off with alcohol. 
For the determination of dosage and the study of reactions and anti- 
body formation  six groups of about 50 men each were chosen  from 
the  various  companies  in  the regiment.  Successive groups received FREDERICK  L.  GATES  453 
increasing  doses of vaccine  in  a  series of three  injections  at  4  to  10 
day intervals according to the schedule in Table I. 
About  25  men  of  Groups  I,  II,  III,  V,  and  VI  gave  preliminary 
(control)  blood samples  for the  study of immunity  reactions  on  the 
day of the first injection and  a  later specimen was obtained from as 
many vaccinated men as were available on the 8th to  10th day after 
the  third  injection. 
At  Major  Johnson's  direction  First  Lieutenant  Serge  Androp, 
Medical  Corps,  obtained  reports  from  the  men  at  inspection  the 
morning  following  the  vaccirrations  in  regard  to  the resulting  local 
and general reactions. 
TABLE  I. 
Vaccination Schedule, Preliminary Series. 
Interval. 
Group No.  1st injection.  Interval.  2nd injection.  Interval.  3rd injection.  Blood samples 
taken. 
I 
II 
III 
IV 
V 
VI 
VII 
millions 
500 
750 
1,000 
1,500 
2,000 
2,000 
2,000 
days 
4 
9 
9 
8 
7 
6 
7 
millions 
1,000 
1,500 
2,000 
3,000 
4,000 
5-6,000 
4,000 
days 
4 
10 
10 
8 
7 
6 
8 
millions 
2,000 
3,000 
4,000 
8,000 
8,000 
10,000 
8,000 
days 
8 
9 
9 
10 
10 
9 
17 
Dosage and Reaction.--The  determination  of the dosage of vaccine 
for subsequent groups followed from the reports of the reactions pro- 
duced by the given doses.  It was considered important  to increase 
the doses gradually in order to locate closely the zone of mild reactions 
and  to  avoid  unexpectedly  severe  results.  Accordingly,  the  vac- 
cinations were begun with the injection of 500 million cocci, and this 
initial  dose was increased in successive groups by 250 or 500 million 
until  it had  reached  2,000  million.  For  the  second and  third  doses 
in  each  group,  the  first dose was usually multiplied  by two and  by 
four.  Thus it usually happened  that  a  given dose had already been 
used as a  second or third in one group before it was tried as the first 
dose in a  later  series. 
Only two reactions of any consequence were reported from doses of 
less than  2,000 million  cocci.  An officer in  Group II who explained 454  ANTIMENINGITIS  VACCINATION 
that  he had  long been hypersensitive  to  foreign protein  and  had  re- 
acted severely to the typhoid and paratyphoid vaccinations developed 
a  severe local and general  reaction,  with headache and malaise,  after 
the first injection of 750  million  cocci.  A  second officer in  Group II 
was  similarly  affected after  a  second injection  of  1,500 million  cocci 
and was confined to bed part of the following day.  The two reactions 
after  these small  doses were merely transient,  but they demonstrate 
a  factor  of  individual  susceptibility  which  was  found  to  be  of  con- 
siderable importance  in the determination  of proper doses of vaccine. 
When  an  initial  dose  of  2,000  million  was  reached  (Group V) 
general  reactions  began  to  appear  with  greater  frequency.  None of 
the men in this group felt ill enough to report at sick call the following 
morning, but nine men stated upon question that they had  felt feverish 
the  preceding  night.  Four  of them  had  had  headache  also  and  one 
reported a  chill.  Arms were moderately sore at  the site of injection, 
but not sore enough to interfere with routine duties. 
From  this  time  on,  a  small  number  of  the  men  in  each  group 
reported  some local or general  discomfort following  the  vaccination. 
The  symptom most  frequently mentioned  was a  "feverish sensation" 
often accompanied by headache,  which was sometimes severe enough 
to  cause  loss  of  sleep.  Morning  temperatures,  when  taken,  were 
reported  normal.  In  a  few  instances  there  was  transient  nausea, 
malaise, or aching joint pains, and  three reactions were initiated with 
a  chill.  Eight  men had  general  reactions  after  the  first  and  second 
doses, or after the second and third,  and three complained of discom- 
fort after all three injections. 
On  the  whole  the  reactions  produced  by' the  vaccine  in  the  pre- 
liminary  series  were  mild  as  compared  with  those  that  occasionally 
follow injections of typhoid or paratyphoid prophylactic and there was 
little  complaint  among  the  men.  The  occurrence  of  an  occasional 
reaction of greater severity even with the smaller doses, and increasing 
local  tenderness  after the injection  of the larger  doses of vaccine led 
to the choice of relatively lower doses for the general  series through- 
out  the  camp  rather  than  the  attempt  to push the dosage up  to  the 
limit  of  endurance.  Later  experience  fully  justified  this  decision. 
Doses  of  2,000,  4,000,  and  8,000  million  had  already  been  decided 
upon when  Group VI was given a  second injection  of 5,000 or 6,000 FREDERICK  L.  GATES  455 
million and a third injection of 10,000 to determine the relative security 
of  the  chosen  doses.  The  injection  ol  10,000  million  cocci  caused 
general reactions in eleven men, but none of them was confined to bed 
or relieved from duty following the injection. 
Finally,  a  seventh  group  of 99  men  received  the  chosen  doses  of 
vaccine  at  weekly intervals  about  a  week before  the  corresponding 
injections were given in the camp at large and served as a  final check 
on  the  dosage.  On  giving  the  third  injections  to  Group  VII it was 
noted  that  many  of the  men  still  had  a  small  painless  area  of sub- 
cutaneous  induration  at  the  site  of  the  former  injections.  This 
persistent  induration ~has been personally  experienced after injection 
of meningococcus vaccine.  It disappears gradually, leaving no trace. 
A  more  general  discussion of reactions  is  reserved  for  the  report  on 
the  larger  vaccination  series. 
Immunity Reactions.--Agglutination  is  the  reaction  of  choice  for 
the study of antibody production  with  the meningococcus.  It is the 
most delicate as well as the most specific, and is most easily made on a 
large number of sera and in multiple dilutions.  In studying agglutina- 
tion,  however,  several  factors have  to  be  taken  into account  aside 
from  the obvious requirement  of a  carefully standardized  technique. 
One  of  the most  important  is  the  relative  agglutinability of various 
strains  of meningococci and  their response to one or both of the type 
(normal  andpara)  immune  bodies.  Meningococci vary also in anti- 
genic power and  not always in  consonance with their agglutinability, 
so that it is sometimes profitable to use certain type strains as antigens 
and other strains  to test antibody production. 
Most of the control sera taken in advance of vaccination from men 
of Groups  I,  II,  III,  V,  and  VI were used  up in  agglutination  tests 
against  the vaccine strains  in a  dilution  of 1: 10.  Except in one in- 
stance in which the para strain was partially agglutinated,  the results 
of these tests were uniforfialy negative.  When the first of the serum 
specimens,  taken  on  the  8th  and  10th  days  after  vaccination  and 
tested in  1:10 dilution  against  the vaccine strains,  also gave negative 
results,  it was decided to collect all the available sera for later study 
in lower dilutions and against more easily agglutinable  strains.  This 
study was  subsequently made  at  The  Rockefeller Institute.  A  cer- 
tain  number  of sera from each  group was examined  by macroscopic 456  ANTIMENINGITIS VACCINATION 
agglutination with a  modification of the Wright method in dilutions of 
1:2  and  higher  against  the  following  strains  from  the  stock  of  The 
Rockefeller Institute: 
No. 8.  A "regular" which is also agglutinated in low dilutions of para serum. 
No. 10.  An intermediate which agglutinates in both "regular" and para serum. 
No. 60.  One of Dopter's  paras  which is relatively easily agglutinable  and was 
represented in the vaccine. 
On account of the limited  amounts  of serum  available  and  the  low 
dilutions  required,  the  following  method  of  agglutination  was  em- 
ployed: 
Capillary glass tubing of an internal diameter of 2 mm. is drawn out into cap- 
sules 8 to 10 cm. long (Fig. 1).  For use the ends are snapped off and a nipple is 
slipped on one end and folded double, giving accurate control of the aspirated fluids. 
A file mark measures equal volumes of serum and salt solution for successive dilu- 
tions, which are made in the capsule and deposited in a  row on a  plate of solid 
paraffin in a  Petri  dish.  The paraffin plate is  conveniently cleaned by melting 
off a  thin layer in hot water.  Equal  amounts of a serum dilution and a meningo- 
coccus suspension  are measured in the capsule, mixed on the paraffin plate, and 
drawn up to form a column about 1 to 1.5 cm. long.  Four or five such specimens, 
separated  by  air  bubbles,  are  sealed  in  a  capsule  for  incubation.  Only  one 
dilution  of a  serum shouldbe used in a  single capsule, but  several meningococcus 
suspensions (4 billion per cc.) may be tested against it, as the admixture of speci- 
mens in the capsule is inappreciable.  The capsules are woven through holes in a 
card which designates their contents, and incubated in a horizontal position for 24 
hours at  55°C.  Complete agglutination is indicated by a widespread  flocculated 
sediment of organisms (Fig. 2).  The flocculi are distributed through the clear fluid 
on rolling the tube briskly between the palms (Fig. 3).  Absence of agglutination 
corresponds  to  a  smooth line  of sediment,  which goes into even  suspension on 
whirling.  Partial  agglutination  is  easily  recognized  in  a  combination  of  the 
two types of sediment.  Results are read with the unaided  eye or under a  small 
hand lens. 
As  stated  above,  most  of the  control  sera  had  been  exhausted  be- 
fore  this  more  comprehensive  series  of tests  was  undertaken.  There 
remained fourteen normal control sera frorh Group VI, and it happened 
that  the practically negative results  obtained  with the sera  of Groups 
I,  II,  and  III  admit  these  specimens  as  controls,  since  the  small 
doses of vaccine used in these groups did not give rise to demonstrable 
antibody formation.  To  these  may  be  added  twelve  sera  from  sup- 
posed  non-contacts  obtained  in  New  York  City. 457 
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TABLE  II. 
Agglutination  Tests with Sera of Vaccinated Men. 
Dilution 1: 2. 
Controls: 
not 
vacci- 
nated. 
N1 
N2 
N3 
N4 
N5 
N6 
N7 
N8 
N9 
N  10 
Nll 
N  12 
Group 
III. 
122 
125 
126 
127 
134 
135 
140 
142 
147 
152 
155 
160 
210 
212 
215 
D  2,59 
240 
246 
250 
251 
252 
253 
254 
255 
256 
257 
259 
261 
262 
263 
264 
267  I 
268 
FREDERICK  L.  GATES 
+ 
+ 
+ 
+  + 
++  ++  - 
-  ++  + 
-  ++  ++ 
++  ++  ++ 
-  ++  + 
-  ++  + 
-  ++  + 
++  ++  + 
-  ++  ++ 
--  +  -- 
++  ++  + 
+  ++  ++ 
++  ++  ++ 
++  ++  ++ 
-  ++  ++ 
-  ++  ++ 
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TABLE  II--Conduded. 
Group 
V I. 
269 
27O 
271 
273 
274 
278 
284 
286 
287 
288 
289 
290 
291 
292 
294 
296 
299 
310 
317 
Before vaccination  (controls). 
Strains. 
8  10  60 
+ 
+ 
+ 
+ 
+  + 
After vaccination. 
Strains. 
8  10  60 
-  +  + 
2+  -  ++ 
+  ++ 
+  ++  + 
+  +++  + 
+  +++  - 
+ 
-  + 
-  +  + 
Group 
VII. 
32,2 
323 
324 
326 
331 
334 
335 
354 
380 
395 
397 
399 
406 
409 
415 
Strains. 
8  I0  60 
-  ++  ++ 
-  +++  ++ 
-  ++ 
-  +++  ++ 
-  + 
-  ++  ++ 
-  ++  ++ 
-  ++  ++ 
-  +++  ++ 
-  + 
-  ++  ++ 
-  ++  + 
-  ++  + 
-  ++  ++ 
+  ++  ++ 
Table  II  shows  the  absence  of  agglutination  in  Groups  I,  II,  and 
III with few exceptions.  In three cases only was more than a  partial 
agglutination of  one  strain  in  the  1 : 2  dilution observed.  The  titers 
in  these cases ran as follows: 
Group. 
I 
II 
Seru in. 
5 
24 
77 
1:32 
0 
1:8 
Strain. 
10 
1:8 
1:32 
1:32 
60 
1:8 
0 
0 
It  may  be  assumed,  therefore,  that  the  number  of  unvaccinated 
men  whose  sera  would  agglutinate  any  of  these  chosen  strains  of 
meningococci  is  small,  and  on  the  basis  of  this  assumption  the  ob- 
servation that twelve of fifteen sera from Group  IV  agglutinate  Strain FREDERICK  L.  GATES  459 
10  partially  or  completely  is  unmistakable  evidence  of  antibody 
formation  through  the  agency  of  the  vaccine.  Group  V,  in  which 
the  dosage reached  that  chosen  for  the  camp  at  large,  confirms  this 
evidence  of  reaction,  for  all  the  twenty-two sera  studied  contained 
antibodies for the meningococcus.  In some instances the more easily 
agglutinable  strains  were  agglutinated  in a dilution  of 1 : 32  or  1 : 64 
(Table III). 
TABLE  III. 
Agglutinin Titers of Sera from Group V. 
Serum. 
227 
233 
234 
237 
239 
240 
246 
25O 
251 
252 
253 
254 
255 
256 
257 
259 
261 
262 
263 
264 
267 
268 
Strains. 
0 
1:2 
1:2 
1:2 
1:2 
1:2 
0 
0 
0 
I: 32 
0 
0 
0 
1:2 
0 
0 
1:2 
1:2 
1:4 
1:2 
0 
0 
lO 
1:32 
1:32 
1:4 
1:16 
1:16 
1:64 
1:2 
1:128 
1:32 
1:64 
1:32 
1:64 
1:32 
1:64 
1:64 
1:2 
1:32 
1:32 
1:32 
1:64 
1:8 
1:64 
60 
1:32 
1:8 
0 
1:4 
1:2 
0 
0 
1:8 
1:32 
1:8 
1:8 
1:8 
1:2 
1:2 
1:16 
0 
1:2 
1:32 
1:32 
1:64 
1:8 
1:8 
The final evidence of antibody production is furnished  by a  direct 
comparison of  sera from Group VI taken before the first vaccination 
with sera  taken 9  days after the  third  injection  of vaccine, in which 
the appearance or increase in agglutinins  is observable in all but two 
instances.  The presence of agglutinins  in  the  sera  from  Group  VII 
merely  confirms  the  previous  findings.  It  may,  therefore,  be  stated 460  ANTIMENINGITIS VACCINATION 
that the injection of well tolerated doses of meningococcus vaccine is .fol- 
lowed by specific antibody formation  in the human body. 
The preliminary series of vaccinations, therefore, served to  estab- 
lish  the method of injection, the proper dosage for extended vaccina- 
tion, the reactions which might be expected to follow the chosen doses, 
and the production of immune bodies in the serum of vaccinated men. 
On the basis of these findings the vaccine was offered to the camp at 
large. 
General Series. 
The  vaccine  used in the general series of inoculations in the camp 
was made by Lieutenant Peter K.  Olitsky at The Rockefeller Insti- 
tute  by  the  methods  already  described.  It  was  shipped  to  Fort 
Riley in bulk  and was  diluted in  isotonic salt  solution to standard 
concentration, preservedwith 0.3 per cent cresol and distributed in 50 
cc. bottles  to  the regimental surgeons under Major Schorer's direc- 
tion.  The use of two suspensions, one of 4,000  million cocci per cc. 
(Vaccine A and B) , and  the other of 8,000  million  (Vaccine C),  ad- 
justed the injection volumes to 0.5 and 1 cc. of Vaccine A and B and 
then  1 cc.  of Vaccine  C,  volumes  similar  to  those for  the  typhoid 
prophylactic, with doses of 2,000  million,  4,000  million,  and  8,000 
million cocci to be given at weekly intervals. 
At  the  direction  of the  Division Surgeon,  the. Division Training 
Officer, Captain Albert Bower,  to whom especial thanks is due for 
his mediation between the regimental surgeons and the laboratory, 
called a  meeting of the surgeons at which the method of giving the 
vaccine and the results to be expected and observed were fullyde- 
scribed and discussed.  The surgeons were thus informed of the pro- 
cedure and object of the vaccination and their cooperation was en- 
listed,  without  which  little  could  have  been  accomplished.  The 
response of the men when the vaccine was offered to them was due in 
large measure to the interest and example of the regimental surgeons. 
According to  the statistics  of the division headquarters, the total 
strength of the 89th Division at this time was approximately 25,000 
officers and men.  Of the~e, 4,792 (19per cent) took the first injection, 
4,257  (17 per cent) the second also, and 3,702  (15 per cent) completed 
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Part of the men received the full dosage as planned.  About half 
of those vaccinated, whose third injection was due after February 4, 
1918, were given a final injection of 4,000 million, on account  of the 
occurrence  of  several  fairly  severe  reactions  from  the  larger  dose 
among medical officers at Fort  Riley.  In  some regiments  the vac- 
cinations had been completed before February 5. 
Reactions.--After  the first injections had  been given,  the opinion 
was almost universal in the camp that the vaccine caused less general 
and local reaction than the typhoid prophylactic.  In very few regi- 
ments was a  man excused from duty the following day on account 
of the reaction from the vaccination.  The general feeling was that the 
second dose caused less reaction than the first, but there  were a few 
men  in  almost  every  organization  who  had  reactions  of moderate 
severity, sometimes being confined to bed for the day with headache, 
joint pains, and nausea.  Several cases of looseness of the bowels or 
transient  diarrhea  were  noted.  This  symptom  had  not  been  en- 
countered before.  Careful inquiry in individual  cases often elicited 
the  information  that men who complained of the effects of vaccina- 
tion  were  suffering  from  mild  coryza,  bronchitis,  etc.,  at  the  time 
of injection. 
Among the units who took the third  injections before the dosage 
was reduced, and so received a  third dose of 8,000 million meningo- 
cocci, there were several instances of fairly severe reactions,  general 
and  local,  which  necessitated  relief  from  duty  the  following  day. 
The  reactions  were  not  more  severe  than  those  that  occasionally 
follow paratyphoid  prophylactic  and  no  untoward  results  were  re- 
ported.  The  large  majority  of  the  men  seem  to  have  suffered no 
appreciable  reaction  whatever.  The  smaller  doses of 4,000  million 
cocci caused  even  fewer reactions. 
As in the preliminary series, the factor of individual susceptibility 
was prominent,  a  few officers and men suffering severely from doses 
which caused no general discomfort in the great majority o'f the men. 
In  general,  the more severe reactions  occurred  among  the  commis- 
sioned officers, and especially among the medical officers at the Base 
Hospital and in the Medical Officers' Training  Camp at Fort Riley, 
due in part  perhaps  to  more  confining  occupations,  higher  nervous 
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men.  In one  regiment,  through a  misunderstanding,  four men were 
given an initial dose of 8,000 million cocci, which was well tolerated. 
The surgeon reported: 
"One had chill for 30 minutes,  headache for 1 hour, slight  local reaction. 
One had slight  headache, slight  local reaction. 
One had severe local reaction and headache for 24 hours. 
One had slight  local reaction, headache for 12 hours." 
A  survey of the reports of the regimental surgeons and of the ob- 
servations in the preliminary series shows that headache was the most 
frequent symptom following injection, and accompanied most of the 
other symptoms encountered.  Sometimes the reaction was initiated 
by a  chill or chilly sensation,  and  a  number of men complained of 
fever or feverish sensations during the following night.  Next in fre- 
quency came nausea  (occasionally vomiting),  dizziness, and  general 
"aches and pains" in the joints and muscles, which in a few instances 
were especially localized in  the neck or lumbar  region,  causing  stiff 
neck or stiff back.  A few injections were followed by diarrhea.  The 
reactions,  therefore,  occasionally  simulated  the  onset  of  epidemic 
meningitis and several vaccinated men were sent as suspects  to  the 
Base Hospital for diagnosis. 
Such  transient  reactions  are  illustrated  by  the  following  brief 
protocols: 
Individual  1.--C. D., Private, Battery D, 342nd Field Artillery. 
Jan. 15,  1918. 1st injection 2,000 million.  "Sore arm." 
Jan. 22.  2nd injection 4,000 million.  "Sore arm, headache." 
Jan. 29.  3rd injection 8,000 million.  "Began to feel badly about 15 minutes 
later and had a chill.  3 hours later was sent to the Base Hospital complaining of 
headache, lumbar pain, stiff neck, and fever, 103°F.  No nausea.  Went to sleep 
about 2 hours later and slept well.  Had entirely recovered the next morning." 
Individual  2.--L. N., Private, Field Hospital  Company  354,  314th  Sanitary 
Train. 
Jan.  21, 1918. 1st injection 2,000 million.  "Slight local  soreness." 
Jan. 28.  2nd injection 4,000 million.  "Slight local soreness." 
Feb. 4.  3rd injection 8,000 million.  "About an hour and a half after injection, 
was taken with a severe chill and a subnormal temperature.  About 20 minutes 
later his temperature rose to 103.6°F. and then fell within the next 2 hours to 101°F. 
Temperature normal the following morning.  He complained of no other symp- 
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The  most  severe  illness  immediately  following  vaccination  is  de- 
scribed by the officer himself as follows: 
Individual 3.--J. M. K., First Lieutenant, 314th Sanitary Train. 
Jan. 21,  1918.  1st injection 2,000 million.  4.30 p.m.  Soreness at site  of in- 
jection in evening.  Slept well. 
Jan. 22.  Awakened feeling drowsy and listless.  Local soreness worse.  Pains 
in back of neck,  calves of legs,  thighs, lumbar region, and both arms.  No ap- 
petite.  Symptoms grew worse after holding sick call at the Infirmary.  Perspired 
on slight exertion.  Felt chilly and warm by turn.  Went to quarters and lay in 
bunk.  Soon  felt  feverish.  Developed  diarrhea  about  i1  a.m.  Eight  move- 
ments in 5  hours.  Cup of hot chocolate at  1 p.m.  Felt nauseated.  Vomited 
six times in next 3 hours.  Took sodium bicarbonate, 2 gm. in glass of  warm water, 
promptly vomited.  Retained  15  minutes later,  and  then  began  to feel  better. 
Felt well next morning but had no appetite.  Bowels still loose.  Returned  to 
duty.  Appetite returned the evening of Jan. 24.  Local soreness persisted 3 days. 
Temperature.  Pulse.  °F. 
Jan.  22,  9.45  a. m .........................................  98.4  86 
1.15 p. m .........................................  99.8  82 
3.45 p. m .......................................  101.0  92 
7.30 p. m  ..................................  .....  101.8  108 
10.00 p. m ........................................  100.0  98 
Jan.  2.3,  7.25  a. m  ........................................  97.8  98 
Jan. 28.  2nd injection 4,000 million.  Local reaction severe.  Duration 3 days. 
General reaction, malaise of 24 hours duration. 
Feb. 4.  3rd injection 8,000 million.  Local reaction severe.  Duration 4 days. 
General  reaction,  nausea,  looseness of bowels  (not diarrhea),  chilliness,  but  no 
fever.  Muscle soreness severe and general.  Appetite absent for 2 days. 
The occurrence of such reactions as those described above was rare 
but they illustrate  the importance of the factor of individual  suscep- 
tibility.  The  great  majority  of the men vaccinated were reported  to 
have had  no general  symptoms,  and  very few men were  confined  to 
quarters after any dose of the vaccine. 
Occurrence of Meningitis after Vaccination.--The records of cases of 
epidemic meningitis in Camp Funston have been followed up to June 4, 
1918,  thus  covering  the  period  that  the  89th  Division  remained  in 
camp.  In  the  interval  between  January  21  when  the  vaccination 
was started in the camp and June 4, 46 cases of meningitis  are reported 
to have entered  the Base Hospital  at Fort Riley.  Of these patients, 
three  had  received  one,  two,  or  three  injections  of  antimeningitis 
vaccine.  The  following  data  have  been  collected in regard to these 
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Case 1.--L. T.,  Second Lieutenant,  314th  Engineers. 
Jan.  21,  1918. 1st  injection  2,000 million.  Next  day neck was rather stiff. 
slight  headache.  Well for next 2 days, but working  very hard on double  duty. 
Jan.  25.  Fainted at Officers' Call.  Felt  "under the weather" with  indefinite 
symptoms the next 2 days but remained  on duty. 
Jan. 28.  2nd injection  4,000 million.  This made him feel so much better that 
he remarked to his friends  that he "was getting to,be a dope fiend in the stuff 
and couldn't get along without it." 
Jan.  29.  Felt  worse  again,  headache,  "no  ambition.':  Following  days  he 
remained  on duty, but tired easily  and often felt  chilly  and feverish,  had stiff 
neck and joint pains. 
Feb.  2.  Remained in bed.  Throbbing headache,  became  nauseated and vom- 
ited twice.  Sent to Base Hospital.  Lumbar puncture on arrival showed a turbid 
fluid with many leukocytes and moderate numbers of intracellular  Gram-negative 
diploeocci. 
Lieutenant T. had a very mild  case of meningitis  which yielded  promptly to 
serum treatment. 
Case 2.--E. H., Corporal,  Company C, 354th Infantry. 
Jan.  21,  1918. 1st injection  2,000 million.  "Never felt  anything.  Arm not 
very sore." 
Jan.  26.  Went on 5  days  leave,  returning  Jan.  31,  and  so  missed  second 
injection. 
Feb.  1.  "Felt sore all over."  Had chills.  Frontal headache. 
Feb.  2.  Headache  continued,  stiff  joints  and  aching  pains.  Sent  to  Base 
Hospital.  Diagnosis,  epidemic  meningitis. 
Corporal H. had a severe case of meningitis but recovered. 
Case 3.--J. C. N., Private, Company B, 340th Machine Gun Battalion. 
Jan. 24,  1918. 1st injection 2,000 million. 
Jan. 31.  2nd injection  4,000 million. 
Feb. 8.  3rd injection  4,000 million.  Reactions not reported. 
Mar. 31.  Acute otitis media and right frontal sinusitis. 
Apr.  16.  Epidemic  cerebrospinal  meningitis. 
Apr. 24.  Cerebrospinal fluid found positive for meningococcus for the last time. 
Apr.  27.  Ulcer of right cornea  followed by slight  opacity with  slight  impair- 
ment of vision. 
May 5.  Right facial paralysis which has since improved considerably. 
Private  N.  will be  ready for assignment  to domestic  military service  about 
July 1, 1918. 
The examples of Lieutenant T  and Corporal H  are instructive,  since 
they may well be,  and probably are,  instances of meningococcus in- 
oculation in individuals in the incubation period of a  meningococcus 
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harm  was  done by the  procedure.  But whether  this  is  the precise 
fact or not, the cases have no real bearing on the value of antimeningi- 
tis vaccination, because the interval between the first inoculation and 
TABLE  IV. 
Agglutination  of Meningococci  in Sera of Vaccinated Men. 
Dilution  1: 2. 
314th  After 
En-  3rd in- 
~neem.  jec~on. 
days 
501  17 
502  17 
503  17 
504  17 
506*  10 
509*  10 
310"  10 
511"  10 
512"  10 
513"  10 
514"  10 
515"  10 
516"  10 
517"  10 
518"  10 
520*  10 
528  18 
531"  10 
532  18 
533  18 
534  18 
Strains. 
8  10  60 
--  -1-  -- 
-  +  + 
-  -++- 
-  -++- 
-  -+  + 
-  ~q-  - 
-  +  + 
-  +  ++' 
+  ~+ ++ 
-  +  + 
--  A I  -  -- 
155  After  Strains. 
[ann: I .3rd.in- 
ry.  Jectton.  8  10  I  60 
"[  days  --' 
5351  15  .... 
536  15  --  ++1  + 
537  15  +  ++1++ 
5381  15  -  ++l+ 
539]  15  .... 
5411  15  --  +TI  -t- 
15  -  ++1 
5471  15  +  ++1 
549  15  +  +, 
553  15  --t  ++1++ 
5581  15  +  ++1 + 
.... 
15  +  +,  -- 
565  15  .... 
566  15  .... 
5681  15  .... 
5691  15  --  ++  + 
5701  15  -  -i- 
5711  15  --  +  --  , 
574  15  --  ++  +] 
576  15  --  ++++! 
578  15  +  ++  + 
581  15  --  ++  + 
583  15  -  +  + 
Tram.  jection___._~. 
586  17 
587  17 
590  17 
591  17 
593  17 
595  17 
598  17 
600  17 
6061  17 
609  I  17 
610  17 
611  17 
612  17 
613  17 
614  17 
615  17 
618  17 
619  17 
622  17 
Strains, 
8  10  60 
-  ++  + 
-  +  + 
q-  --  -- 
-  +  + 
-  ++ ++ 
+  ++ ++ 
-  +  + 
--  ++ ++ 
-  ++ ++ 
--  ++ ++ 
+  ++  + 
-  ++ ++ 
--  ++ ++ 
-  ++ ++ 
+  ++ ++ 
-  ++ ++ 
-  +  + 
* 3rd dose 4,000 million cocci. 
the diagnosis of the meningitis was too  brief to permit  immunization 
to be effected. 
It is clear that Private N  developed meningitis  at  a period at which 
protection  following  vaccination  should  have  been present.  In his 
case  the  vaccination must  be  considered  as  having  failed  to  afford 466  ANTIMENINGITIS VACCINATION 
protection.  A study of the type of the infecting meningococcus would 
conceivably have thrown light  on the incident,  or the incident may 
merely indicate  that occasional individuals fail to be adequately im- 
munized, just as in the ahalogous procedure of antityphoid inoculation. 
Immunity  Reactions,  General Series.--In  addition  to  the  blood 
samples  taken  for  study  in  the  preliminary  series  of  vaccinations, 
similar samples were obtained from a group of men in  each of three 
regiments  who  had  completed  the  vaccination  series.  The  serum 
specimens were  taken at an interval of from 10 to 18 days after the 
third  injections had been given,  and were examined  for agglutinins 
bv  the  method  already  described.  The  results  of  these  tests  are 
shown in  Table  IV.  The  sera of  50 men  showed  some content  of 
agglutinins;  the sera of 16 others failed to do so. 
Examination for Agglutinins of the Blood Serum of Chronic  Carriers. 
While  every case  of  epidemic meningitis  is  presumed  to  develop 
from the carrier  state, many observers have noted the rarity  of the 
disease among chronic carriers.  The presence of the meningococcus 
in  the nasopharynx  is but one of the factors in  the  accident  which 
results in the bacterial invasion of the body, and  the relatively low 
infectivity of the meningococcus is to be credited  to  causes of resis- 
tance on the part  of the  carrier  host among  which  may well be the 
appearance of immune bodies in the blood as the result of the multi- 
plication of meningococci in the nasopharynx. 
If the  presence  of  agglutinins  for  the  meningococcus  could  be 
demonstrated  in  the  blood of chronic  carriers,  light  would  thereby 
be thrown on the mechanism of this resistance.  With the object  of 
detecting the possible existence  of meningococcus agglutinins  in  the 
blood serum of carriers, a number of such sera have been studied in low 
dilutions  by  the  capsule  method  described in  an  earlier  section of 
this report. 
Through the courtesy of Passed Assistant Surgeon J. L. Waterman, 
United States Naval Hospital, Brooklyn NavyYard, and Dr. F. S.West- 
moreland,  Riverside Hospital, New York, opportunity was given to 
obtain blood samples from a number of chronic carriers  of the menin- 
gococcus, and the corresponding carrier strains were kindly furnished FREDERICK  L.  GATES  467 
by Dr. A. W. Williams of the Department of Health,  of the City of 
New York, or obtained directly from the men themselves.  The men 
studied were known to have harbored meningococci for from 4 to 16 
weeks. 
20 carrier strains of the meningococcus have been subjected to the 
agglutination tests in low dilutions with the sera of the hosts from 
whom they were obtained and the carrier sera were tested against the 
stock strains of spinal origin that had been studied in the sera of vac- 
cinated men from Camp Funston.  18 of the carrier strains were also 
TABLE  V. 
Control  Agglutination  Tests with Normal Sera  against  Carrier  Strains. 
Dilution  1:2 
Normal contro]  Carrier Strains. 
serlIm. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
124 
-I 
+ 
F+ 
+ 
+ 
52[ 1~  Z 
--J  Jr 
--i  -- 
+1--1- 
+ 
+  +  +- 
-  -  -i  + 
L 
136  139  141  147 
+ 
....  ++  _~ 
--i  --i  ~ 
--i  --i  --  I 
....  +l++  ....  ++ 
....  +  + 
+1  ~ 
?1  +,-  -,- 
-  -;-I 
-_  -i 
-  _- 
-I  I 
--  --I  -- 
--  --i  -- 
+  -  +1+ 
)-  + 
I 
* No  test. 
tested with  12  normal sera from supposed non-contacts as controls. 
The results of these tests are recorded in Tables V to IX.  The trials 
with non-contact sera (Table V) show that with two  exceptions the 
carrier strains are not usually agglutinated in normal sera in a  1 : 2 
dilution.  One of the exceptional strains was partially or completely 
agglutinated by 9  and  the  other by 8  of  the  12  sera.  The  other 
cultures were only occasionally agglutinated in this low dilution of 
normal serum.  One supposedly normal serum agglutinated 11 of the 
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all  but  4  of these  carrier  strains  were  agglutinated  (Table VI)  and 
the sera in most instances showed agglutinins for stock spinal strains of 
the meningococcus.  Subsequently the sera were reexamined in multi- 
ple dilutions,  and at this  time  2  of  those  previously found  negative 
agglutinated  their  strains  up  to  1:4  and  1:8  (Table  VII).  The 
titers of the other sera ran from 1 : 4 to 1 : 64. 
TABLE  VI. 
Agglutination  of Homologous  Nasal Strains and  Stock Spinal  Strains in Sera of 
Carriers. 
Serum of. 
Carrier  2 
~c  3 
~c  6 
~  9 
"  11 
"  13 
"  16 
"  18 
"  25 
"  27 
"  28 
"  29 
"  30 
"  36 
"  39 
cc  40 
"  41 
"  43 
"  48 
"  50 
Homologous nasal 
strains. 
++ 
+ 
++ 
+ 
++ 
++ 
+ 
+ 
++ 
++ 
++ 
+ 
+ 
++ 
+ 
++ 
++ 
+ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
+ 
++ 
+ 
+ 
+ 
++ 
Spinal Strains. 
10 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
++ 
+ 
+ 
++ 
60 
++ 
++ 
+ 
++ 
++ 
+ 
+ 
++ 
++ 
++ 
+ 
Appearance  of  Agglutinins  in  Sera  after  Storage.--On  numerous 
occasions we have observed an increase in agglutinating power in sera 
which  have  stood  at ice box temperature  for some time.  The  fact 
was  reported  in  a  recent  paper  9 as  having  occurred  with  typhoid 
agglufinins  in guinea pig sera,  and  Tulloch  4 records  an instance  in 
9 Gates, F.L., Antibody production after partial adrenalectomy in guinea pigs, 
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TABLE  VII. 
Agglutination  of Carrier Strains in Homologous  Sera. 
Homologous  Agglutination titers. 
Serum of.  Strain.  --  -  -- 
.....  1:2  1:4  1:8  1  6  1  ]  1:64 
Carrier  2  124  ++  +  + 
"  3  125  +  +  + 
"  6  127  +  ++  +  -  4- 
"  9  128  ++  ++  ++  -  ~-  bb  +-{-+ 
"11  129  +++  +++  ++  - 
"  13  133 
"  16  134  ++  ++  ++  . 
"  18  136  ++  ++  +  • 
"  27  139  ++  ++  + 
"  28  ~41  I  ++  I  ++  1  +  I  I 
36  ÷+  ÷  +  ÷÷ 
"39  150  ++  +_{+  +++ 
""  151  ~  + 
+ 
"  ~1  153  ++  *  + 
"  43  J  156 
"  46  [  160  ++  ++  ++  -  ~-  ++ 
"  48  [  161  ++  ++  ++ 
"  50  ]  162  /  ++  I  +  /  -  [  ] 
* No specimen. 
TABLE  VIII. 
Appearance of Agglutinins  in Carrier Sera after Storage. 
Dilution 1: 2. 
~rum  drawn 
May  24,  1918. 
16 
36 
39 
40 
41 
43 
46 
50 
Examination  of May  29.  Examination  of June  12.  Examination  of June  24. 
Spinal Strains. 
o  . 
~.~ 
m 
m 
D 
m 
m 
10  6O 
m 
R 
_  ,  A  V 
Spinal  Strains.  o 
~.  , 
~  s  i  i0  60  ~ 
+  ++  ++  + 
++  ++  + 
+  + 
Spinal Strains.  o 
fl "~  8  10  60 
++  No test. 
++  -  +  + 
--  m 
--  D 
m  -- 
m  -- 
i 
m  m 
+  - 
No test. 
I-I- 
i 
m 
++i  - 
++  - 
++  - 
++  - 
++  ++ 
++  ++ 
++  ++ 
-  ++ 
+  + 
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rabbit  serum  during  immunization  to  the  meningococcus.  Thishe 
explains as due to the presence of constituents of the serum or of the 
organisms which do not take part in the mechanism of agglutination, 
but which may be present "in such quantity or in such a physical state 
that  they protect the united antibody-antigen complex from the floc- 
culating action of the  electrolytes." 
Table VIII shows the appearance of agglutinins in some of the sera 
under discussion after they had stood, sealed, at 4°C. for some time. 
The  other  sera  were  not  examined  so  early  after  bleeding.  The 
TABLE  IX. 
Agglutination  of Stock Strains in Sera of Carriers. 
Serum of. 
Carrier  27 
"  28 
"  36 
"  39 
"  40 
"  41 
"  43 
"  46 
"  48 
"  50 
Agglutination  titers of homol- 
ogous strains in rabbit serum. 
Normal.  Para. 
1: 400+  1:400 
1: 400+  1:100 
1: 400+  1:50 
1 : 800  1 : 100 
1: 400+  1:50 
1 : 400+  1 : 100 
1 : 50  1 : 100 
I : 800  1 : 200 
1 : 50  1 : 100 
1: 400+  0 
Agglutination titers of stock spinal strains 
in carrier sera. 
No. 8 
1:2 
0 
0 
0 
0 
0 
0 
0 
0 
0 
No. 10 
1  16 
1:32 
1:64 
1:32 
1:64 
1:32 
1:32 
0 
1:32 
1:8 
No. 60 
1:16 
1:4 
1:4 
1:64 
0 
1:8 
1:8 
I: 16 
1:8 
1:2 
inconstancy  of the phenomenon  has  already been described ° and  is 
implied by Tulloch in his reference to "this particular  serum." 
A  variation  of a  different order was  encountered when ten of the 
sera studied on May 29 or June 12 were examined on June  24 in mul- 
tiple dilutions with the stock spinal strains  (Table IX).  Six of the 
ten had agglutinated  Strain 8 in the  1:2 dilution.  Now all but one 
serum failed to do so.  Strains 10 and 60, however, were agglutinated 
in various serum dilutions by practically all the specimens examined, 
including  No.  43,  which  had  failed  to  agglutinate  its  homologous 
strain.  Agglutinins for these spinal strains  are only rarely found in 
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DISCUSSION. 
Heretofore  meningococcus vaccines have  not  been  extensively employed for 
prophylactic immunization,  and  only a  few  references  are to  be  found  in  the 
literature that relate vaccination experiences.  Davis,  TM in 1907, describing animal 
experiments and the therapeutic use of an autogenous vaccine reported a personal 
experience in which he suffered a very severe zeaction following the subcutaneous 
injection of a  24  hour slant culture of a  meningococcus heated to 65°C.  for 30 
minutes.  Shortly after  inoculation,  nausea  and  vomiting were  followed by  a 
severe  chill, lasting half an  hour,  and  then  intense headache,  muscular pain, 
purging, and vomiting of bile.  His temperature rose to 103°F., and during the 
remainder of the day, and in the night following, nausea and vomiting continued, 
with  headache,  thirst,  and  marked  prostration.  Later  symptoms  included  a 
diffuse rash, herpes, and in the urine granular, hyaline, and epithelial casts.  The 
reaction subsided gradually.  The leukocytes rose to 44,050 on the 3rd day, and 
the opsonic index reached 2.3 on the 2nd day, returning to normal by the 5th day. 
Sophian and Black  n  studied agglutination and complement fixation in serum 
specimens from ten students who had been vaccinated with two or three doses of a 
monova]ent vaccine.  The doses given were 500 or 1,000  million, 1,000  or 2,000 
million, and 2,000 million cocci, at 7 day intervals.  Their vaccine had been heated 
to  50°C.  for  1  hour.  Following the  vaccinations they noted  malaise, frontal 
headache, and slight fever with occasionally more severe symptoms; intense fron- 
tal or vertical headache, general bodily pain, nausea, vomiting, and a rise of tem- 
perature to  102-104°F.  Labial herpes was seen.  Using a  readily agglutinable 
organism,  they  found the  agglutinin titers of the sera of their vaccinated sub- 
jects to range from  1 : 200  to  1:  1,500.  Complement was fixed in serum  dilu- 
tions up to  1 : 250.12  Complement-fixing antibodies were found in low dilutions 
of the serum of seven of these men after an interval of 2 years. 
Sophian and Black refer to Hall's experience in Kansas City in the vaccination 
of about 280 persons in families in which meningitis had occurred.  A number of 
doctors and nurses were likewise inoculated, and in no instance did the disease 
occur subsequent to vaccination.  About 100 persons in Dallas were vaccinated, 
but most of them did not complete the vaccination series.  Two nurses developed 
epidemic meningitis some weeks after a series of two inoculations; both recovered. 
10 Davis, D. J., Studies in meningococcus infections, J.  Infect.  Dis.,  1907,  iv, 
558. 
11 Sophian,  A.,  and  Black,  J.,  Prophylactic  vaccination  against  epidemic 
meningitis, J. Am. Med. Assn., 1912, lix, 527.  Black, J. H., Prophylactic vacci- 
nation against epidemic meningitis, J. Am. Med. Assn.,  1914,  lxiii, 2126. 
12 Such  figures  must  be  accepted  with  reserve.  They  are  far  higher  than 
laboratory experience would lead one to expect after such prophylactic doses of a 
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Recently Whitmore, Fennel, and Petersen  TM have reported an experience with a 
polyvalent lipovaccine  in which  total doses of 40,000 million  or 80,000 million 
cocci were given subcutaneously in one or two injections.  55 men in all were 
vaccinated.  40,000  million cocci in one dose did not cause any general reaction. 
Two doses of 40,000 million cocci each at a 3 day interval were followed by two 
instances of constitutional reaction among 25 men.  5 men received 80,000 mil- 
lion  cocci in a  single injection which  was followed after 24 hours by a moderate 
general  reaction.  In  the  first  days  after  vaccination  with  the  larger doses 
agglutinin formation was  observed against  three of the  vaccine  strains, espe- 
cially those that respond to antibodies of both the normal and the para type. 
These reports from the literature coincide with the present experi- 
ence with meningococcus vaccine in their descriptions of the reactions 
that  may be  expected, and  of the  appearance  of specific antibodies 
in  the blood after vaccination.  As Sophian and Black pointed out, 
the  general  symptoms  indicate  some  degree  of meningeal  irritation 
and  occasionally  they may  simulate  the  onset  of meningitis.  The 
symptoms are not progressive, however, and even though severe, they 
clear up in a few hours.  In one instance in which  a  lumbar puncture 
was done on a suspect 3 days after a secdnd dose of vaccine the  spinal 
fluid was found normal.  The illness described by Davis is  instructive 
to show the severity of  the symptoms which may follow an injection 
of meningococcus substance many times the proper dose.  Whitmore, 
Fennel, and  Petersen, by  protecting  their vaccine in oil, were able to 
give much larger doses in a  single injection with  only moderate con- 
stitutional effects. 
Whatever may be the relation of agglutinins  to specific protection 
against  invasion  the  agglutination  test  is  recognized  as  the  most 
reliable indication of antibody formation due to the meningococcus, 
and is used generally in the standardization of therapeutic sera as an 
index  of  potency.  With  equal  reason  the  presence  of  agglutinins 
may be taken as an index of active immunization after vaccination. 
We do not know the ratio of agglutinin formation to protective power, 
and  can  only  discover  by  wide  experience  what  agglutinin  titers 
correspond  to  relatively  complete  immunity  to  meningococcus  in- 
vasion.  It is perhaps significant, however, that the agglutinin titers 
13 Whitmore,  E.  R.,  Fennel, E.  A.,  and  Petersen, W.  F.,  An  experimental 
investigation of lipovaccines:  a preliminary note,  J.  Am. Med. Assn.,  1918, lxx, 
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of the sera of vaccinated men are of the same order of serum dilutions, 
namely 1 : 4  to 1 : 64+, as those of chronic carriers of the meningo- 
coccus, who are usually refractory to the strains carried.  A study of 
the blood of cases of meningitis which have recovered without serum 
treatment might be instructive in this connection. 
Meningococcus  agglutinins  appear  not  to  have  been  found  pre- 
viously in the blood of chronic carriers.  Cathoire,  14 in a brief communi- 
cation,  reported  that the  agglutinin study of carrier  sera led  to  no 
positive result, but with the Wright technique he was able to show a 
constant increase in opsonic power compared with sera from normal 
persons,  and  he  therefore concluded that  the  relative immunity of 
carriers is to be explained by a specific change in the serum. 
Herrick  15  thinks that  the occurrence of relapses  in  some  cases  of 
epidemic  meningitis  "lends  discouragement  to  vaccine  prophylaxis 
and other measures for  the production of immunity."  It should  be 
pointed  out  that  relapses  are  probably  caused by  reinfection from 
small pockets in the meninges in which the meningococcus has been 
walled off, and so permitted to survive therapeutic measures otherwise 
effective.  It  may be  mentioned in  passing  that  the  occurrence  of 
relapses in typhoid fever has been no contraindication to the employ- 
ment of  typhoid prophylaxis.  The  object  of prophylactic vaccina- 
tion is to oppose the meningococcus at the threshold, and if a systemic 
invasion precedes the spinal infection, as recent observations tend to 
show, the building up of antibodies in the blood stream is the means 
by which a hematogenous incursion is to be combated. 
SUMMARY. 
1.  A  meningococcus vaccine  suspended  in  salt  solution has  been 
given subcutaneously as a prophylactic to about 3,700  volunteers in 
three  injections of  2,000  million, 4,000  million,  and  4,000  or  8,000 
million cocci at weekly intervals. 
2.  These doses rarely caused more than the mildest local and general 
reactions.  Exceptionally  a  more  severe  reaction  emphasized  the 
14 Cathoire, E., Recherche  du pouvoir opsonisant du s~rum des porteurs sains 
de m~nlngocoques, Compt.  rend.  Soc.  biol.,  1910, lxix, 240. 
15 Herrick, W. W., The intravenous  serum treatment of epidemic cerebrospinal 
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presence of an  unusual  individual susceptibility  to  the  vaccine.  In 
such  instances the  symptoms were in part those of  meningeal  irrita- 
tion and sometimes simulated the onset of meningitis. 
3.  Specific meningococcus agglutinins  have been  demonstrated  in 
the blood serum of vaccinated men as compared with normal controls. 
4.  Moreover,  agglutinins  have  been  demonstrated  in  the  blood 
serum  of chronic carriers of  the  meningococcus.  Evidence  is  thus 
brought  forward  that  the  relative  immunity  of chronic  carriers  to 
epidemic meningitis may be due to the presence of specific antibodies 
in  the blood stream. 
EXPLANATION OF PLATES. 
PLATE 47. 
FIG. 1.  Capsule of glass tubing of 2 ram. internal diameter showing points at 
which it is snapped off for use, and file mark for measuring equal volumes of serum 
and meningococcus suspension. 
FIG. 2.  Appearance of agglutination specimens  after incubation.  (a) Com- 
plete agglutination.  (b)  No agglutination.  (c)  Partial agglutination. 
PLATE 48. 
Fro. 3.  Appcarance of completely agglutinated specimens  after shaking. THE JOURNAL  OF  EXPERIMENTAL  MEDICINE VOL.  XXVlll.  PLATE 47. 
FIG.  1.  Fro. 2. 
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FIo. 3. 
(Gates: Antimeningitis vaccination.) 